“Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s616, https://doi.org/10.25251/n1p8w126.